Explore the latest NSCLC new treatments in development, including candidates aimed at tackling hard-to-treat, late-stage lung ...

A panelist discusses how the MARIPOSA, SKIPPirr, and COCOON studies highlight the significant overall survival benefit of the ...

A post hoc analysis shows significantly improved ORR and PFS in advanced NSCLC with higher AFM24 exposure, supporting ...

The Ventana TROP2 RxDx Device, a computational companion diagnostic, was granted breakthrough device designation by the FDA ...

Taletrectinib can be effective in patients with TKI-naïve or TKI-pretreated advanced NSCLC, a pooled analysis suggests.

Zongertinib elicited meaningful results in previously treated patients with HER2-mutated, advanced non–small cell lung cancer ...

Zongertinib, an oral therapy shown to have strong responses in patients previously treated for HER2 -mutated non–small cell ...

The Small Cell Lung Cancer market report also offers comprehensive insights into the Small Cell Lung Cancer market size, ...

Ingelheim, Germany Wednesday, April 30, 2025, 14:00 Hrs [IST] ...

Opdivo (nivolumab) is a brand-name IV infusion prescribed for non-small cell lung cancer (NSCLC) in some situations. This article covers topics such as side effects, dosage, and how Opdivo works.

Explore the evolving landscape of non-small cell lung cancer (NSCLC) treatment, where targeted therapies address ten actionable genomic alterations (AGAs). Discover innovations in EGFR mutations, ...